research Long-term hair loss associated with brentuximab vedotin–containing chemotherapy and its psychosocial impact: A retrospective observational study conducted at the Royal Marsden Hospital.
This study found that nearly 40% of Hodgkin’s Lymphoma patients who received Brentuximab Vedotin with AVD chemotherapy experienced persistent alopecia more than two years after treatment, leading to significant psychosocial consequences such as reduced self-confidence and emotional distress.

